CMB International issued a report stating that Giant Biotech announced on May 17 that it would sell 49 per share.midwayarcadetreasures.4 Hong Kong dollars placed 33.22 million shares, accounting for approximately 3.23% of the company's enlarged share capital. The placing price represented a discount of approximately 6.7% to the closing price on May 16. The net proceeds from the placing are expected to be approximately HK$1.627 billion, with approximately 90% intended for core businessmidwayarcadetreasuresDevelopment and ecosystem layout. The bank expects that the company will use sufficient cash reserves to build brand influence and further enrich the product line layout. The bank estimates that collagen rods will account for more than 30% of the revenue of the Kefu brand in 2023, and expects new products such as the Kefu Focus Series and the Kolejin Film Series to be rapidly increased during the promotion period.

CMB International pointed out that the company's product cycle is upward and it looks forward to promoting bright performance; it continues to be optimistic about the continued growth of online sales of Giant Biofunctional Skin Care Products, and expects injectable collagen products to be approved within the year. Based on the DCF model, the bank raised its target price from HK$57.14 to HK$60.83, maintaining its "Buy" rating.